REFERENCES
- Martinez E, Garcia-Viejo MA, Blanch L, Gatell JM. Lipodys-trophy syndrome in patients with HIV infection: quality of life issues. Drug Saf. 200124: 157–166.
- Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000;10:546–550.
- Yang Y, Sitoh YY, Tha NO, Paton NI. Facial fat volume in HIV-infected patients with lipoatrophy. Antivir Ther. 2005;10:575–581.
- Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-in-fected adults: a case-control study. Lancet. 2003;361:726–735.
- Lemieux L, Liu RS, Duncan JS. Hippocampal and cerebel-lar volumetry in serially acquired MRI volume scans. Magn Reson lmag. 2000;18:1027–1033.
- Yang Y, Wilder-Smith A, Panchalingam A, Tha NO, Paton NI. Changes in body fat measured by DEXA in patients taking different formulations of stavudine. HIV Clin Trials. 2005;6:337–343.
- Martin A, Smith D, Carr A, et al. Progression of lipodystro-phy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study). HIV Clin Trials. 2004;5:192–200.
- Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005;40:121–131.
- Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002288: 207–215.
- McComsey GA, Ward DJ, Hessenthaler SM, et al. Im-provement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263–270.
- Martin A, Smith DE, Carr A, et al. Reversibility of lipoatro-phy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029–1036.
- Bergersen BM, Sandvik L, Ellingsen I, Bruun JN. Lipo-atrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive. HIV Med. 2005;6:260–267.
- Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003;33: 22–28.
- Ribera EJ, Paradiniero J, Sauleda S, et al. Improvement of subcutaneous fat, lipid profile, and parameters of mi-tochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir. the LIPOTEST Study. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22–25, 2005; Boston, Massachusetts. Abstract 860.
- Padilla S, Gallego JA, Masia M, Gutierrez F. Single-slice computed tomography and anthropometric skinfold analysis for evaluation of facial lipoatrophy in HIV-infected patients. Clin Infect Dis. 2004;39:1848–1851.
- Paton NI, Macallan DC, Jebb SA, et al. Longitudinal changes in body composition measured with a variety of methods in patients with AIDS. J Acquir Immune Defic Syndr Hum RetroviroL 1997;14:119–127.